Barclays analyst Gena Wang downgraded Spark Therapeutics to Equal Weight from Overweight while raising her price target for the shares to $115 from $74. The analyst cites the pending takeover by Roche (RHHBY) for the downgrade.
https://thefly.com/landingPageNews.php?id=2883447
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.